CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Janssen Biotech Inc. v. Par Pharmaceutical Inc.

1:15-cv-00679

Overview

Case Number 1:15-cv-00679
Filing Date 2015-08-03
Status Terminated
Termination Date 2015-10-28
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand None

Parties

Defendant

Par Pharmaceutical Companies Inc. Operating Company

Represented By

0 Attorneys Listed
No attorneys available

Par Pharmaceutical Inc. Operating Company

Represented By

0 Attorneys Listed
No attorneys available

Amneal Pharmaceuticals of New York LLC Operating Company

Represented By

0 Attorneys Listed
No attorneys available

Amneal Pharmaceuticals LLC Operating Company

Represented By

0 Attorneys Listed
No attorneys available

Plaintiff

Janssen Research & Development LLC Operating Company

Represented By

2 Attorneys Listed

Andrew Colin Mayo

Ashby & Geddes

Tel: +1 (302) 654-1888

Ashby & Geddes, 500 Delaware Avenue, 8th Floor

Steven J. Balick

Ashby & Geddes

Tel: +1 (302) 654-1888
Fax: +1 (302) 654-2067

Ashby & Geddes, 500 Delaware Avenue, 8th Floor

Janssen Oncology Inc. Operating Company

Represented By

2 Attorneys Listed

Andrew Colin Mayo

Ashby & Geddes

Tel: +1 (302) 654-1888

Ashby & Geddes, 500 Delaware Avenue, 8th Floor

Steven J. Balick

Ashby & Geddes

Tel: +1 (302) 654-1888
Fax: +1 (302) 654-2067

Ashby & Geddes, 500 Delaware Avenue, 8th Floor

Janssen Biotech Inc. Operating Company

Represented By

2 Attorneys Listed

Andrew Colin Mayo

Ashby & Geddes

Tel: +1 (302) 654-1888

Ashby & Geddes, 500 Delaware Avenue, 8th Floor

Steven J. Balick

Ashby & Geddes

Tel: +1 (302) 654-1888
Fax: +1 (302) 654-2067

Ashby & Geddes, 500 Delaware Avenue, 8th Floor

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360Β° Radar 11 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

πŸ‡ΊπŸ‡Έ
U.S. District Courts Counterparts in force
πŸ›οΈ
USPTO PTAB Trials Counterparts in force
πŸ‡ͺπŸ‡Ί
Unified Patent Court (UPC) Counterparts in force
πŸ‡©πŸ‡ͺ
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (11): πŸ‡ΊπŸ‡Έ US
Parallel Proceedings Across Jurisdictions (0 found):

No active co-pending lawsuits found across other jurisdictions for this family. All related sibling filings are currently unlitigated.

Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

1 Patent

There is a single patent involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US8822438
Methods and compositions for treating cancer
Filed: 2011-02-24
Issued: 2014-09-02
Active (4.3 yrs remaining)
Expires: 2031-02-24

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. Β§ 283) Active Threat

Active Threat β€” Patent is within enforceable statutory term; injunctive relief viable.

Terminal Disclaimer & Cellect Risk Low Risk

Standard Statutory Term β€” No obviousness-type double patenting noted.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. 4th & 8th Year Maintenance Fees Paid (12th Year Window Upcoming).

Docket Entries

(16 total)
Pleading / Complaint

COMPLAINT filed against Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals of New York LLC, Par Pharmaceutical Companies Inc., Par Pharmaceutical Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 311-1764333.) - filed by Janssen Oncology Inc., Janssen Biotech Inc., Janssen Research & Development LLC. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Civil Cover Sheet)(dmp, ) (Entered: 08/04/2015)

Entry #1 • 2015-08-03
1

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (dmp, ) (Entered: 08/04/2015)

Entry #2 • 2015-08-03
1

Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - see attached form (Entered: 08/04/2015)

Entry #3 • 2015-08-03
1

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,822,438 B2;. (dmp, ) (Entered: 08/04/2015)

Entry #4 • 2015-08-03
1

CORRECTING ENTRY: Corrected text for DI3 and regenerated NEF to attorneys (dmp, )

Entry #5 • 2015-08-03
1
No Actions

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc